Integra closes its first round with funds from Spain and Japan

Integra Therapeutics (Integra Tx), a biotechnology company that develops state-of-the-art gene editing tools that improve the effectiveness of advanced genetic therapies, has closed an investment round of 1.5 million euros led by the Valencian venture capital manager Columbus Venture Partners. This investment completes the contribution of 4.5 million euros made in December by the funds, Invivo (Spain) and Takeda (Japan).

You can read the full story at the following link.